NCT07387965

Brief Summary

The goal of this clinical trial is to learn if providing eating disorder patients with education about the consequences of cannabis (marijuana) use on mental health, gastrointestinal symptoms, eating disorder symptoms, and eating disorder treatment effectiveness increases their knowledge about the cannabis use consequences, intention to reduce cannabis use, and motivation to seek treatment for their cannabis use. The main questions this study aims to answer are:

  1. 1.Does education about consequences of cannabis use increase eating disorder patients' knowledge about the risks of cannabis use?
  2. 2.Does education about the consequences of cannabis use increase intention to reduce cannabis use and seek cannabis use treatment among those with eating disorders?
  3. 3.Does cannabis use interfere with how successful eating disorder treatment is for eating disorder patients?

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
21mo left

Started Feb 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Feb 2026Feb 2028

First Submitted

Initial submission to the registry

January 13, 2026

Completed
22 days until next milestone

First Posted

Study publicly available on registry

February 4, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

February 4, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 4, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 4, 2028

Last Updated

February 4, 2026

Status Verified

January 1, 2026

Enrollment Period

2 years

First QC Date

January 13, 2026

Last Update Submit

January 27, 2026

Conditions

Eating DisordersCannabis Use

Keywords

single blindsingle blind randomized control trialrandomized control trialeating disorderscannabis usepsychoeducationbrief interventionmarijuanacannabisbinge eating disorderanorexia nervosabulimia nervosa

Outcome Measures

Primary Outcomes (3)

  • Knowledge of cannabis use consequences

    Self-perceived knowledge about consequences of cannabis use will be measured using a 100 point visual analogue scale. Higher scores will indicate greater self-perceived knowledge about the consequences of cannabis use.

    Will be measured at baseline (i.e. 5 minutes into Session 1 of treatment for eating disorders before cannabis psychoeducation is administered), and again at 140 minutes into Session 1 of treatment for eating disorders.

  • Intention to reduce cannabis use

    Intention to reduce personal cannabis use will be measured using a 100 point visual analogue scale. Higher scores indicate greater intention to reduce cannabis use.

    Will be measured at baseline (i.e. 5 minutes into Session 1 of treatment for eating disorders before cannabis psychoeducation is administered), and again at 140 minutes into Session 1 of treatment for eating disorders.

  • Intention to seek cannabis use treatment

    Intention to seek cannabis use treatment will be measured using a 100 point visual analogue scale. Higher scores indicate greater intention to seek cannabis use treatment.

    Will be measured at baseline (i.e. 5 minutes into Session 1 of treatment for eating disorders before cannabis psychoeducation is administered), and again at 140 minutes into Session 1 of treatment for eating disorders.

Secondary Outcomes (5)

  • Motivations for cannabis use

    Measured at baseline (i.e. Week 1 of CBT for eating disorders) and through treatment completion (i.e. Week 20 of CBT for eating disorders).

  • Cannabis use frequency

    Weekly use will be monitored for 20 weeks using a Likert-type question. The Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory will be measured twice during Week 1 and Week 20 of CBT for eating disorders

  • Eating disorder symptoms

    Administered at Week 1 (baseline) and Week 20 of CBT for eating disorders.

  • Impairment caused by eating disorder

    Administered at Week 1 and Week 20 of CBT for eating disorders.

  • Problematic cannabis use

    Administered at Week 1 and Week 20 of CBT for eating disorders.

Study Arms (2)

Cannabis psychoeducation intervention

EXPERIMENTAL

Brief psychoeducation will be provided to eating disorder patients seeking treatment regarding the impact of cannabis use on comorbid mental health conditions, sleep, gastrointestinal symptoms, eating disorder symptoms, and eating disorder treatment outcomes.

Other: Psychoeducation about risks of cannabis use

Psychoeducation control condition

PLACEBO COMPARATOR

Brief psychoeducation will be provided to eating disorder patients seeking treatment regarding the impact of poor sleep on mental health outcomes and appropriate sleep hygiene habits.

Other: Placebo control: Sleep hygiene psychoeducation

Interventions

Psychoeducation about risks of cannabis useOTHER

This intervention will provide psychoeducation to eating disorder patients about the risks of using cannabis on mood, anxiety, sleep, substance use, gastrointestinal symptoms, eating disorder symptoms, and eating disorder treatment outcomes.

Cannabis psychoeducation intervention
Placebo control: Sleep hygiene psychoeducationOTHER

Eating disorder patients in the control condition will receive psychoeducation about impacts of poor sleep on mental health and eating disorder treatment outcomes, and strategies to improve sleep hygiene.

Psychoeducation control condition

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • A patient of St. Joseph's Healthcare Hamilton Eating Disorder Program (i.e. is currently seeking eating disorders treatment)
  • Participant has been diagnosed with an eating disorder
  • Aged 16+
  • Understands written and spoken English

You may not qualify if:

  • Has not been diagnosed with an eating disorder
  • Under the age of 17
  • Does not understand written and spoken English

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Joseph's Healthcare Hamilton, West 5th Campus

Hamilton, Ontario, L8N 3K7, Canada

Location

MeSH Terms

Conditions

Feeding and Eating DisordersMarijuana AbuseBinge-Eating DisorderAnorexia NervosaBulimia Nervosa

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and SymptomsMental DisordersSubstance-Related DisordersChemically-Induced Disorders

Study Officials

  • Sarah McComb, Ph.D., C. Psych

    St. Joseph's Healthcare Hamilton

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sarah McComb, Ph.D., C. Psych

CONTACT

905-522-1155smccomb@stjoes.ca

Keisha Gobin, Ph.D., C. Psych

CONTACT

905.522.1155kgobin@stjoes.ca

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 13, 2026

First Posted

February 4, 2026

Study Start

February 4, 2026

Primary Completion (Estimated)

February 4, 2028

Study Completion (Estimated)

February 4, 2028

Last Updated

February 4, 2026

Record last verified: 2026-01

Locations

CA(1)